On this ground, we were prompted to test the antimetastatic properties of the more soluble NBD derivative, MC3181, against melanoma cells lines derived from the primary lesion (WM115) and a skin metastasis (WM266.4) of a single patient harboring a BRAF-V600D mutation. This evidence concerns the gene BRAF and melanoma.